TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06294912
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets to be administered orally as definitive antimalarial treatment.
Study: NCT06294912
Drug: Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Study: NCT06294912
Drug: Atovaquone/proguanil
Normalized name: ATOVAQUONE/PROGUANIL
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets to be administered orally as definitive antimalarial treatment.
Study: NCT05686408
Drug: TNX-601 ER
Normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet orally once daily for 6 weeks.
Study: NCT06785935
Drug: Corticosteroid: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasonography-guided corticosteroid injection under the A1 pulley
Study: NCT06423352
Drug: Zilebesiran
Normalized name: Zilebesiran
DrugBank: Zilebesiran (DB18929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilebesiran administered by subcutaneous (SC) injection
Study: NCT05376800
Drug: BI 907828 (Brigimadlin)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 907828 (Brigimadlin)
Study: NCT06046040
Drug: TmPSMA-02 CAR T Cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
Study: NCT05343754
Drug: Hyperbaric oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperbaric treatment will consist of 30 daily treatments in the first 6 weeks of the study, except during the weekends. After compression for 10 minutes patients will receive 80minutes (4 times 20 minutes) 100% O2 with 3 airbrakes (21% O2) of 5 minutes at 2.4-2.5 ATA, and then 10 minutes decompression with the first part of decompression till 0.3 ATA with 100% oxygen (this will usually take seven minutes). The last 0.3 ATA will be decompressed with air. In total one hyperbaric session will be 110 minutes. Treatment will start directly at the beginning of the study.
Study: NCT04554888
Drug: Doxepin Topical
Normalized name: doxepin topical
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
Study: NCT04554888
Drug: Papain
Normalized name: Papain
DrugBank: Papain (DB11193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papain will be applied by 1 SPT prick thought the skin
Study: NCT04554888
Drug: Histamine
Normalized name: Histamine
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine will be applied by 1 SPT prick thought the skin
Study: NCT04817670
Drug: VIT-2763 120 mg
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive 2 capsules of VIT-2763 30 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally.
Study: NCT04817670
Drug: VIT-2763 360 mg
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive 2 capsules of VIT-2763 60 mg in the morning, in the afternoon and in the evening for 8 weeks.~Capsules are to be taken orally.
Study: NCT04817670
Drug: VIT-2763 240 mg
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive 2 capsules of VIT-2763 60 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally.
Study: NCT05655598
Drug: Palbociclib Oral Product
Normalized name: palbociclib Oral Product
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle
Study: NCT05655598
Drug: TAS-116
Normalized name: TAS-116
DrugBank: TAS-116 (DB14876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
Study: NCT05655598
Drug: TAS-116
Normalized name: TAS-116
DrugBank: TAS-116 (DB14876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
Study: NCT05655598
Drug: TAS-116
Normalized name: TAS-116
DrugBank: TAS-116 (DB14876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
Study: NCT04686539
Drug: CBD
Normalized name: CBD
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBD oil not containing THC, to be administered sub-lingual.
Study: NCT05547828
Drug: Tislelizumab combined with chemoradiotherapy
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)
Study: NCT05320640
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide is a novel and orally active benzamide class of HDAC inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, which can induce tumor-cell apoptosis, suppress cell proliferation and enhance immune surveillance.
Study: NCT05320640
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose decitabine inhibits the activity of DNA methyltransferase, which can increase tumor antigens and HLA expression, enhance antigen processing, promote T cell infiltration, and boost effector T cell function.
Study: NCT05022303
Drug: Larazotide Acetate
Normalized name: Larazotide
DrugBank: Larazotide (DB05645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
Study: NCT05379179
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
Study: NCT04657003
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05902988
Drug: VLS-1488
Normalized name: VL-2397
DrugBank: VL-2397 (DB17796)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VLS-1488 tablets will be given orally.
Study: NCT05415215
Drug: Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PH FDC SC is administered subcutaneously (SC) as a fixed non-weight-based dose. A loading dose of 1200 milligram (mg) pertuzumab, 600 mg trastuzumab, and 30,000 units of recombinant human PH20 hyaluronidase (rHuPH20) is given in the first cycle (1 cycle is 21 days). In subsequent cycles, maintenance doses of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units rHuPH20 are administered once every 3 weeks (Q3W).
Study: NCT05415215
Drug: Pertuzumab IV
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab is given as a fixed dose of 840 mg intravenous (IV) loading dose and then 420 mg IV for subsequent maintenance doses once every 3 weeks.
Study: NCT05415215
Drug: Trastuzumab Emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine will be given at a dose of 3.6 mg/kg by intravenous (IV) infusion, once every 3 weeks.
Study: NCT05434156
Drug: ELE-101
Normalized name: HYDROXYPROPYL CELLULOSE (TYPE EL)
DrugBank: Hydroxypropyl cellulose (DB00840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELE-101 solution for intravenous infusion
Study: NCT06679556
Drug: Strength A Sublingual Minoxidil
Normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One single dose of Strength A sublingual minoxidil
Study: NCT06679556
Drug: Strength B Sublingual Minoxidil
Normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One single dose of Strength B sublingual minoxidil
Study: NCT05116085
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04325802
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg Naltrexone daily
Study: NCT06090266
Drug: OR502
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.
Study: NCT06090266
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
Study: NCT05493111
Drug: AR-15512 vehicle ophthalmic solution
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients administered via topical ocular instillation
Study: NCT06192693
Drug: Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day).~FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%.
Study: NCT05527418
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib monotherapy 70 mg/day, during 16 weeks.
Study: NCT06295822
Drug: Nuan-gong-ye
Normalized name: Cha Ye
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.
Study: NCT05233397
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For \< 30 kg: 12 mg/kg IV every 2 weeks; For ≥30 kg: 8 mg/kg IV every 2 weeks
Study: NCT05045482
Drug: Saroglitazar Magnesium 1 mg
Normalized name: pitavastatin magnesium 1 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-8: Total of 18 subjects will be enrolled in the Group-8. Group 8A (n=6, consist of mild hepatic impairment subjects); Group 8B (n=6, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).
Study: NCT05045482
Drug: Saroglitazar Magnesium 2 mg
Normalized name: pitavastatin magnesium 2 MG
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
Study: NCT06351540
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
Study: NCT04774718
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive twice-daily alectinib capsules on Days 1-28 of each 28-day cycle
Study: NCT04703686
Drug: Obinutuzumab
Normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000mg - prephase - one infusion at D-3
Study: NCT04703686
Drug: RO7082859
Normalized name: Anti-CD20/CD3 bispecific monoclonal antibody RO7082859
DrugBank: Glofitamab (DB16371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg D1C1, 10 mg D3C1, then 30 mg D8C1 and D1 every 21 days (C2-C11, D1C2 starts 14 days after D1C1)
Study: NCT05470595
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
Study: NCT05367245
Drug: Cal-Mag Butyrate
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplements
Study: NCT05971940
Drug: Orforglipron
Normalized name: Orforglipron
DrugBank: Orforglipron (DB18964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05731947
Drug: Revumenib
Normalized name: Revumenib
DrugBank: Revumenib (DB18515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
Study: NCT05837845
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a flexible divided-dose of MDMA HCl plus therapy at three Experimental Sessions, as well as non-drug Preparatory and Integration Sessions
Study: NCT05647889
Drug: Jet lidocaine
Normalized name: lidocaine Jet Injector
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jet lidocaine will be applied before PVC and PVC will be performed 3 minutes later.
Study: NCT05009082
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Area under curve (AUC) 5, intravenous, on day 1 every 3 weeks for 6 cycles
Study: NCT05544240
Drug: SV-101
Normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.
Study: NCT05009082
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m², intravenous, on day 1 every 3 weeks for 6 cycles
Study: NCT06119061
Drug: Telavancin Injection
Normalized name: telavancin Injection
DrugBank: Telavancin (DB06402)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telavancin 10mg/kg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).
Study: NCT04173169
Drug: Elagolix 200 MG
Normalized name: elagolix 200 MG
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix tablet
Study: NCT05951400
Drug: Dydrogesterone Tablets
Normalized name: Dydrogesterone Tablets
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: used for pituitary suppression in ICSI cycle
Study: NCT05951400
Drug: Cetrorelix
Normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist for pituitary suppression
Study: NCT05945420
Drug: Desmopressin Acetate
Normalized name: Desmopressin Acetate
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This arm will receive tamsulosin and desmopressin acetate daily a
Study: NCT06308952
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible subjects screened will enter the pretreatment period (days 1 to 4) and be randomly assigned to the trial group (oral atorvastatin) or the control group (placebo) to start receiving the trial drug (20mg, qd). At the same time, the patient was started on basic dual antibody therapy (aspirin 75mg qd + clopidogrel 75mg qd/ticagrelor 45mg bid).
Study: NCT05130086
Drug: Islatravir
Normalized name: Islatravir
DrugBank: Islatravir (DB15653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
Study: NCT05594459
Drug: high opioids dosages
Normalized name: high-density polyethylene
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be treated with high opioids dosages
Study: NCT05711810
Drug: Nifedipine 30 MG
Normalized name: nifedipine 30 MG
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.
Study: NCT05711810
Drug: Enalapril Maleate 10Mg Tab
Normalized name: ENALAPRIL MALEATE 10MG TAB
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.
Study: NCT05711810
Drug: Lansoprazole 30Mg Ec Cap
Normalized name: LANSOPRAZOLE 30MG EC CAP
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.
Study: NCT05711810
Drug: Metoprolol Succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.
Study: NCT05711810
Drug: Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release
Normalized name: DULOXETINE HYDROCHLORIDE 20 mg ORAL CAPSULE, DELAYED RELEASE
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine hydrochloride is used for the patient's neurodiverse conditions.
Study: NCT05711810
Drug: Superoxide Dismutase
Normalized name: Superoxide dismutase
DrugBank: Orgotein (DB11444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superoxide Dismutase is used to substitute the missing of antiviral drugs.
Study: NCT06102005
Drug: Lunsekimig
Normalized name: Lunsekimig
DrugBank: Lunsekimig (DB19009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Study: NCT05075265
Drug: Methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard dose of 0.2 ug/kg before Cardiopulmonary Bypass.
Study: NCT05009082
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 mg/kg or 15 mg/kg (according to local standard), intravenous, on day 1 every 3 weeks starting from cycle 2 in combination with chemotherapy and thereafter for up to 1 year
Study: NCT06785116
Drug: Dapagliflozin 10mg Tab
Normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will take this daily for 6-months. Additionally, during the study participants will have 4 study visits and be asked to complete study specific activities (i.e. daily blood pressure, weekly weights, laboratory draws, echocardiograms, etc.) Participants will be followed remotely for 1-month after the 6-month visit.
Study: NCT06725277
Drug: Spravato
Normalized name: Spravato
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intranasal esketamine
Study: NCT06725277
Drug: IV Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ketamine
Study: NCT05422027
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor (ATG-010# is a first-in-class, oral selective exportin 1 (XPO1) inhibitor (1,2). Selinexor functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus along with inhibition of translation of oncoprotein mRNAs.~Selinexor dose escalation: 40, 60mg respectively on day 1,8,15 for 21 days cycles
Study: NCT05766683
Drug: onabotulinumtoxinA at a depth of 2mm
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 2mm
Study: NCT05766683
Drug: onabotulinumtoxinA at a depth of 4mm
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time administration of onabotulinumtoxinA to the corrugator supercilii muscles bilaterally. Dosing dependent on the baseline mass and volume of subject's glabellar muscles as assessed by trained cosmetic dermatologist, accounting for symmetry/asymmetry of the face and can range from 10-50 units. Will be administered at a depth of 4mm
Study: NCT05422027
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The investigators gave patients subcutaneous bortezomib 1.3mg/sqm on days 1, 8,15 of a 21- day cycle.~standard bortezomib-lenalidomide-dexamethasone
Study: NCT05096481
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
Study: NCT05422027
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The investigators gave patients oral lenalidomide 25mg on days 1 to 14 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone
Study: NCT05422027
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The investigators gave patients oral dexamethasone 40mg on days 1, 8, 15 of a 21-day cycle.~standard bortezomib-lenalidomide-dexamethasone